Answers are grounded in this paper and cite their sources.
Background and Objective Patients managed with trimodal therapy (TMT) for muscle-invasive bladder cancer (MIBC) remain at risk of intravesical recurrences. This retrospective analysis evaluates the efficacy and safety of dose escalation compared to standard dose radiotherapy, with differentiation between invasive and non-invasive local control. Methods A multicentre retrospective analysis was conducted on patients with MIBC who underwent TMT with contemporary radiotherapy techniques from 2015 to 2025. Patients in the standard dose cohort received either 55Gy in 20 fractions or 64Gy in 32 fractions. In the dose-escalation cohort, a simultaneous integrated boost approach was undertaken to deliver up to 60Gy in 20 fractions or 70Gy in 32 fractions to the primary lesion. The effect of dose escalation compared with standard dose on 2-year local control for invasive and non-invasive disease, metastasis-free survival, overall survival, bladder preservation, and toxicity was investigated. Results The cohort consisted of 107 patients with a median follow-up of 23 months. Dose escalation was significantly associated with improved local control of invasive disease (SHR 0.20 [0.05, 0.89], p = 0.035) compared to standard dosing, after adjusting for T stage. There were no differences in local control for non-invasive disease (p=0.8), metastasis-free survival (p=0.8) and overall survival (p=0.5). Both groups tolerated radiotherapy well, with no difference in grade 2 or greater genitourinary and gastrointestinal toxicity (p=0.8, p=0.9, respectively). No patients receiving dose escalation required salvage cystectomy for invasive disease recurrence, compared with two patients who received standard dosing. Conclusion Preliminary evidence suggests efficacy of dose escalation with good tolerability, high rates of bladder preservation, and potentially lower rates of invasive recurrences compared with standard dose radiotherapy. This study's findings support the need for further prospective studies to evaluate dose escalation as a technique to maximise the efficacy of TMT.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: